Coronary Artery Disease Clinical Trials & Research Studies Near You (Updated 3/25)

Peripheral Nerve Blocks for Above-the-knee Amputations

NCT03404180

Recruiting

Surgery performed with nerve blocks and sedation may be safer and provide better pain control compared to general anesthesia and opioid therapy in high-risk patient populations such as elderly and troubled with peripheral vascular disease, diabetes, hypertension, coronary artery disease, and chronic obstructive pulmonary disease (COPD).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/22/2024

Locations: University of Florida, Gainesville, Florida

Conditions: Peripheral Vascular Diseases, Hyperglycaemia (Diabetic), Hypertension, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive

Register for Updates

Learn More ›

PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG

NCT06567795

Recruiting

To evaluate the proportion of diabetic mellitus patients with CV events as measured by HEMOTAG.

Gender:

ALL

Ages:

40 years and above

Trial Updated:

08/21/2024

Locations: Metabolic Research Institute, Inc, West Palm Beach, Florida

Conditions: Diabetes Mellitus Type 2, Cardiovascular Diseases, Coronary Artery Disease, Cerebrovascular Disease, Peripheral Artery Disease

Register for Updates

Learn More ›

South Asians and Coronary Plaque Registry

NCT05367297

Recruiting

Individuals who self-report as SAs will be recruited to participate in this registry as well as non-SA controls for comparison. All individuals who consent to participate will 1) complete a survey assessing demographics, medical history, family medical history; 2) have blood collection; 3) and CCTA assessment. These data will be combined with clinical data from the electronic health record and, if applicable, the Dallas Hearts and Mind Study and other research studies, for research purposes. The... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/15/2024

Locations: University of Texas Southwestern Medical Center, Dallas, Texas

Conditions: Coronary Artery Disease, Heart Diseases

Register for Updates

Learn More ›

WARRIOR Ancillary Study for CCTA Analysis

NCT05035056

Recruiting

In this study, quantitative characterization of plaque using coronary computed tomographic angiography (CTA) will be used to determine if women who were treated with intensive medical therapy have a greater reduction in the amount and type of cholesterol plaque compared to women receiving usual care and if this results in beneficial changes in clinical symptoms. The study will provide an understanding of how intensive medical therapy works in providing clinical benefit in women with nonobstructi... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

08/15/2024

Locations: Cedars-Sinai Medical Center, Los Angeles, California

Conditions: Coronary Artery Disease, Non-Obstructive Coronary Atherosclerosis, Ischemia

Register for Updates

Learn More ›

PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]

NCT05994014

Recruiting

Early detection of coronary atherosclerotic disease facilitates adequate prevention. The purpose of this study is to compare an assessment of coronary atherosclerotic disease burden by positron emission tomography / computed tomography (NaF-PET/CT) with those of conventional and ultra-high-resolution-CT (UHR-CT) in patients with suspected coronary artery disease. For this purpose, the investigators plan to include 33 patients with symptoms concerning for CAD who have been referred for cardiac CT... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/13/2024

Locations: Johns Hopkins Hospital, Baltimore, Maryland

Conditions: Coronary Artery Disease, Atherosclerosis, Coronary Atherosclerosis of Native Coronary Artery

Register for Updates

Learn More ›

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

NCT04124120

Recruiting

The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grfating (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing coronary artery bypass grfating (CABG). The investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocar... Read More

The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grfating (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing coronary artery bypass grfating (CABG). The investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocardial infarction, repeat revascularization, and hospital readmission for acute coronary syndrome or heart failure) in a cohort of 2,000 women randomized 1:1 to MAG or SAG (690 from the parent ROMA trial + 1,310 from ROMA:Women). Differences by important clinical and surgical subgroups (patients younger or older than 70 years, diabetics, racial and ethnic minorities, on vs off pump CABG, type of arterial grafts used) will also be evaluated. The women enrolled in the ongoing ROMA trial (anticipated to be approximately 690) will be included in ROMA:Women, increasing efficiency and reducing enrollment time. Hypothesis 1.0. MAG will reduce the incidence of major adverse cardiac and cerebrovascular events. Hypothesis 1.1. The improvement with MAG will be consistent across key subgroups. Aim 2: Determine the impact of MAG vs SAG on generic and disease-specific QOL, physical and mental health symptoms in women undergoing CABG. The investigators will compare generic (SF-12, EQ-5D) and disease-specific (Seattle Angina Questionnaire) QOL and physical and mental health symptoms (PROMIS-29) in a sub-cohort of 500 women randomized 1:1 to MAG or SAG (including those enrolled in ROMA:QOL). Differences by important subgroups (as defined above) will also be evaluated. Hypothesis 2.0. MAG will improve generic and disease-specific QOL compared to SAG. Hypothesis 2.1. MAG will improve physical and mental health symptoms compared to SAG. Hypothesis 2.2. The improvement with MAG will be consistent across key subgroups. Read Less

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

08/05/2024

Locations: Cedars-Sinai Medical Center, Los Angeles, California +123 locations

Cedars-Sinai Medical Center, Los Angeles, California

University of Colorado, Aurora, Colorado

Yale University Hospital, New Haven, Connecticut

Emory University, Atlanta, Georgia

University of Chicago, Chicago, Illinois

Johns Hopkins University, Baltimore, Maryland

Baystate Health, Springfield, Massachusetts

University of Massachusetts Chan Medical School, Worcester, Massachusetts

Washington University in St. Louis, Saint Louis, Missouri

Nebraska Heart Hospital, Lincoln, Nebraska

Methodist Physicians Health, Omaha, Nebraska

University of Nebraska Medical Center, Omaha, Nebraska

Englewood Health, Englewood, New Jersey

Newark Beth Israel Medical Center, Newark, New Jersey

The Valley Hospital, Ridgewood, New Jersey

NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York

Weill Cornell Medicine, New York, New York

Icahn School of Medicine, Mount Sinai, New York, New York

Columbia University Medical Center, New York, New York

Lenox Hill Hospital, New York, New York

New York Presbyterian Queens, Queens, New York

Duke University, Durham, North Carolina

Cleveland Clinic Foundation, Cleveland, Ohio

Ohio State University, Columbus, Ohio

University of Pennsylvania, Philadelphia, Pennsylvania

Allegheny General Hospital, Pittsburgh, Pennsylvania

Lankenau Medical Center, Wynnewood, Pennsylvania

Rhode Island Hospital, Providence, Rhode Island

Baylor Scott & White Research Institute, Dallas, Texas

Baylor College of Medicine, Houston, Texas

UT Health San Antonio, San Antonio, Texas

University of Utah, Salt Lake City, Utah

The University of Melbourne, Melbourne, Not set

Medical University of Graz, Graz, Not set

Innsbruck Medical University, Innsbruck, Not set

Kepler University Hospital, Linz, Not set

Medical University of Vienna, Vienna, Not set

Krankenhaus Nord Vienna North Hospital, Vienna, Not set

Institute of Cardiology Porto Alegre, Porto Alegre, Not set

Heart Institute University of São Paulo, São Paulo, Not set

Instituto Dante Pazzanese de Cardiologia, Vila Mariana, Not set

St. Boniface General Hospital, Winnipeg, Manitoba

Horizon Health Network - Saint John Regional Hospital, Saint John, New Brunswick

NL Health Services, St. John's, Newfoundland and Labrador

Hamilton General Hospital, Hamilton, Ontario

London Health Sciences, London, Ontario

University of Ottawa Heart Institute, Ottawa, Ontario

Health Sciences North, Sudbury, Ontario

Sunnybrook Health Sciences, Toronto, Ontario

Toronto General Hospital, Toronto, Ontario

Montreal Heart Institute, Montréal, Quebec

University Hospital of Montreal, Montréal, Quebec

Royal Victoria Hospital, Montréal, Quebec

Institut Universitaire de Cardiologie et de Pneumologie de Québec, Ste Foy, Quebec

Hopital Sacre-Coeur, Montréal, Not set

Fraser Clinical Trials, New Westminster, Not set

Fuwai Hospital China, Beijing, Beijing

Jilin Heart Hospital China, Changchun, Jilin

Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai

Teda Hospital Tianjin China, Tianjin, Tianjin

University Hospital Dubrava, Zagreb, Not set

University Hradec Králové, Hradec Králové, Not set

General University Hospital, Prague, Nové Město, Not set

Aalborg University Hospital, Aalborg, Not set

Rigshospitalet, Copenhagen, Not set

Universitäts-Herzzentrum Bad Krozingen Freiburg, Bad Krozingen, Baden-Wuerttemberg

HDZ NRW Bad Oeynhausen Germany, Bad Oeynhausen, Not set

Deutsches Herzzentrum der Charite, Berlin, Not set

Essen University, Duisburg, Not set

Duisburg Heart Center, Duisburg, Not set

Dusseldorf University, Düsseldorf, Not set

University Hospital Erlangen, Erlangen, Not set

Essen University, Essen, Not set

Frankfurt University, Frankfurt, Not set

University Hospital of Giessen and Marburg, Gießen, Not set

University Medical Center of Göttingen, Göttingen, Not set

Jena University Hospital, Jena, Not set

Heart Center Herzzentrum, Leipzig, Leipzig, Not set

Robert-Bosch-Hospital Stuttgart Germany, Stuttgart, Not set

Krankenhaus der Barmherzigen Brüder Trier, Trier, Not set

G Kuppuswamy Naidu Memorial Hospital (GKNM), Coimbatore, Tamil Nadu

Star Hospitals - Hyderabad, India, Hyderabad, Telangana

Rambam Health Care Campus, Haifa, Not set

Anthea Hospital, Bari, Not set

Humanitas Gavazzeni of Bergamo, Bergamo, Not set

Fondazione Poliambulanza, Brescia, Not set

Maria Cecilia Hospital GVM, Cotignola, Not set

Careggi University Hospital, Florence, Not set

European Hospital, Roma, Not set

Universita' Cattolica del Sacro Cuore, Roma, Not set

Ospedale Le Molinette, Torino, Torino, Not set

Tokyo Medical and Dental University, Bunkyō-Ku, Tokyo

Saitama Medical University Japan, Saitama, Not set

Seoul National University Hospital, Seoul, Not set

Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seúl, Not set

Maastricht University Medical Centre, Maastricht, Not set

Acibadem-Sistina Hospital, Skopje, Not set

Medical University of Silesia, Katowice, Not set

Zbigniew Religa Lower Silesian Heart Disease Centre, Zabrze, Not set

University Hospital Coimbra, Coimbra, Not set

Centro Hospitalar Lisboa Ocidental, Lisboa, Not set

Centro Hospitalar e Universitário Sao João, Porto, Not set

National Research Medical Center of the Russian Academy of Sciences - Tomsk, Russia, Tomsk, Not set

Dedinje Cardiovascular Institute, Belgrade, Not set

National University of Singapore, Singapore, Not set

Hospital Universitario del Vinalopo, Elx, Alicante

Hospital Clinic de Barcelona, Barcelona, Not set

Hospital Clinico de San Carlos, Madrid, Not set

NavarraBiomed, Pamplona, Not set

Sahlgrenska University Hospital, Gothenburg, Not set

National Taiwan University Hospital, Zhongzheng, Taipei

Oxford University Hospitals NHS Trust, Multiple Locations, Oxford

NHS Golden Jubilee, Clydebank, Not set

The Royal Infirmary of Edinburgh, Edinburgh, Not set

Hull University Hospitals, Hull, Not set

University Hospitals of Leicester, Leicester, Not set

Liverpool Heart and Chest Hospital Foundation Trust, Liverpool, Not set

Guy's and St Thomas' NHS Foundation Trust, London, Not set

Imperial College Healthcare NHS Trust, London, Not set

St George's University Hospitals, London, Not set

Manchester University NHS Trust, Manchester, Not set

South Tees Hospitals NHS Trust, Middlesbrough, Not set

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, Not set

Royal Wolverhampton NHS Trust, Wolverhampton, Not set

Conditions: Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting

Register for Updates

Learn More ›

AI Detection of Incidental Coronary Artery Calcium to Enhance Cardiovascular Disease Prevention

NCT06235112

Recruiting

AI INFORM is a multicenter randomized trial that will test the hypothesis that providing clinicians information on the presence and amount of coronary artery calcifications (CAC), will result in initiation or intensification of preventive therapies. The study will use a cloud-based artificial intelligence (AI) platform (Nanox.AI) that can analyze non contrast chest CT and estimate the amount of CAC.

Gender:

ALL

Ages:

Between 40 years and 75 years

Trial Updated:

08/05/2024

Locations: Brigham and Women's Hospital, Boston, Massachusetts

Conditions: Coronary Artery Disease

Register for Updates

Learn More ›

Ultra-high-resolution CT vs. Conventional Angiography for Detecting Coronary Heart Disease

NCT04272060

Recruiting

Cardiac catheterization with invasive coronary angiography is the gold standard for determining the presence or absence of significant coronary heart disease (CHD). However, cardiac catheterization is costly and, as an invasive procedure, it is associated with some risk of adverse events, rarely even stroke, myocardial infarction, or death. Recent advances in multi-detector computed tomography angiography (CTA) have allowed rapid, noninvasive coronary artery imaging in patients with suspected CH... Read More

Cardiac catheterization with invasive coronary angiography is the gold standard for determining the presence or absence of significant coronary heart disease (CHD). However, cardiac catheterization is costly and, as an invasive procedure, it is associated with some risk of adverse events, rarely even stroke, myocardial infarction, or death. Recent advances in multi-detector computed tomography angiography (CTA) have allowed rapid, noninvasive coronary artery imaging in patients with suspected CHD. CTA generally yields high accuracy for identifying patients with CHD when compared to cardiac catheterization. However, diagnostic accuracy is reduced in the setting of severe coronary artery calcification and coronary stents due to its inferior spatial resolution compared to cardiac catheterization. Because high-risk patients often have severe coronary calcification or stents, the application of CTA has been particularly limited in this important patient group. Recently, an ultrahigh-resolution CT scanner was released which has shown promise to overcome the limitation of conventional CTA in the setting of severe coronary artery calcification or stents. This ultrahigh-resolution "precision" CT scanner (UHR-CT) contains detector rows with half the width than currently available systems (0.25 mm vs. 0.5 mm) resulting in approximately twice the spatial resolution. The purpose of this investigation is to test the hypothesis that high-resolution CTA is not inferior to the current standard of cardiac catheterization for identifying significant CHD in patients with high-risk characteristics, including severe coronary artery calcification and coronary stents. The investigators propose to enroll 50 patients over 24-30 months in this investigation as part of a multicenter study. Patients referred for cardiac catheterization with known CHD and suspected obstructive coronary artery stenosis will be included. All patients will undergo both cardiac catheterization and UHR-CT for determining significant CHD as defined by coronary functional assessment. The primary end point will be the diagnostic accuracy by area-under-curve (AUC) method for identifying patients with hemodynamically significant CHD. Read Less

Gender:

ALL

Ages:

Between 45 years and 85 years

Trial Updated:

07/26/2024

Locations: Johns Hopkins Hospital, Baltimore, Maryland

Conditions: Coronary Artery Disease

Register for Updates

Learn More ›

Telehealth Group Counseling and Preventive Care for Women

NCT06404515

Recruiting

The purpose of this study is to utilize an innovative healthcare delivery strategy via telehealth group counseling sessions to improve engagement, adherence, and ultimately outcomes in female patients with atherosclerotic cardiovascular disease (ASCVD).

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

07/22/2024

Locations: Weill Cornell Medicine, New York, New York

Conditions: ASCVD, NSTEMI, STEMI, Coronary Artery Disease, Acute Coronary Syndrome, Myocardial Infarction, Unstable Angina, Chest Pain

Register for Updates

Learn More ›

The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial

NCT05618353

Recruiting

Heart disease remains the leading cause of death in Veterans. Inflammation in the arteries of the heart may increase the risk of cardiac death. Patients with heart disease undergoing major surgery are at increased risk of complications after surgery, including heart attack, stroke, and death. The proposed research seeks to better understand the role of inflammation in the damage to the heart and blood vessels after major surgery. This research also seeks to identify the potential beneficial role... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/05/2024

Locations: Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama +5 locations

Conditions: Coronary Artery Disease

Register for Updates

Learn More ›

Assessment of Patients With suspeCted Coronary Artery Disease by Coronary calciUm fiRst strATegy vErsus Usual Care Approach.

NCT03972774

Recruiting

The cost of medical care in the United States far exceeds that of all other advanced economies and continues to accelerate at a rate unacceptable to our society, due primarily to the high costs of new imaging technologies and novel drugs (1). Cardiac positron emission tomography (PET) imaging is a powerful new modality for the non-invasive detection of provocable coronary ischemia in patients with low to intermediate-risk chest pain or its equivalent. Intermountain Medical Center (IMC) is perfor... Read More

The cost of medical care in the United States far exceeds that of all other advanced economies and continues to accelerate at a rate unacceptable to our society, due primarily to the high costs of new imaging technologies and novel drugs (1). Cardiac positron emission tomography (PET) imaging is a powerful new modality for the non-invasive detection of provocable coronary ischemia in patients with low to intermediate-risk chest pain or its equivalent. Intermountain Medical Center (IMC) is performing approximately 6000 clinical cardiac PET scans annually. However, cardiac PET scans are expensive (i.e., billed at >$5,000/scan, average receivable revenue $1500-$2000/scan). Coronary artery calcium (CAC) is a sensitive marker of coronary atherosclerosis. A CAC scan (CACS), performed by multislice computed tomography (CT), is a relatively inexpensive (~$70-$150/scan), low-radiation dose test that marks the presence of coronary atherosclerotic plaque. The absence of CAC has been shown to be associated with very low coronary risk. ACCURATE will test whether a CAC-first strategy (i.e., risk stratification, when CAC ≤ 1, to medical management or to cardiac PET stress testing), performed routinely in symptomatic patients presenting for evaluation of possible coronary artery disease (CAD) prior to the cardiac PET stress test, can be used as a gatekeeper for progression to the expensive rubidium-PET stress (regadenoson) perfusion scan and be a major cost-saver without adversely affecting patient care or outcomes. Routinely, qualifying patients undergo CACS when they present for evaluation of possible but unknown CAD status and are referred for cardiac PET stress testing. In ACCURATE, those with CACS≤1 will then be consented and randomized to either a cardiac PET stress test strategy or a non-PET-driven medical care strategy. Subjects randomized to the cardiac PET stress test strategy will receive appropriate subsequent care depending on the outcome of the cardiac PET scan (i.e., depending on whether ischemia is present or not). Subjects randomized to the CAC-only arm will receive appropriate non-PET driven medical clinical management and follow-up. All participating subjects' electronic medical records will be reviewed indefinitely for clinical outcomes. Initial outcomes will be reported at 1-year, 2-years, and 5-years, with future analyses to be determined by the study investigators. The objective of this study is to test the hypothesis that PET stress test strategy will results in a decreasing in major adverse cardiac endpoint without exceeding $100,000 per quality-adjusted life year compared to a CAC-first strategy for screening suspected/possible coronary artery disease. Read Less

Gender:

All

Ages:

50 years and above

Trial Updated:

05/23/2024

Locations: Intermountain Healthcare Hospitals and Clinics, Salt Lake City, Utah

Conditions: Coronary Artery Disease

Register for Updates

Learn More ›

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health

NCT05819814

Recruiting

The goal of this randomized controlled trial is to assess the impact of disclosing a high polygenic risk result for coronary artery disease on change in cardiovascular health over one year.

Gender:

All

Ages:

Between 40 years and 75 years

Trial Updated:

05/08/2024

Locations: Massachusetts General Hospital, Boston, Massachusetts

Conditions: Coronary Artery Disease

Register for Updates

Learn More ›

Coronary Artery Disease Clinical Trials

Match to Clinical Trials